💊 Pharmaceuticals — Top Stocks by Market Cap
1,859 companies · updated every 5–20 min
Pharmaceutical and biotech stocks on this page cover drug manufacturers and related healthcare innovators, ranked by market capitalisation. Large-cap pharma often mixes defensive cash-flow businesses with pipeline-driven growth names. Scan the sector leaders here, then open a company page for deeper market data.
We currently track 1,859 companies in Pharmaceuticals worldwide. Eli Lilly and Company leads with a market cap of $1.22T, followed by Johnson & Johnson ($662.49B) and AbbVie Inc. ($513.86B). Combined, the top 100 companies on this page are worth $8.57T.
| # | Name | Price | 24h % | 7d % | Market Cap | Volume (24h) | Last 7 Days |
|---|---|---|---|---|---|---|---|
| 1 | $1373.70 | +6.63% | +7.65% | $1.22T €1.10T | 4.36M shrs $5.98B | ||
| 2 |  Johnson & Johnson JNJ🇺🇸USD | $275.20 | +1.53% | +6.23% | $662.49B €593.06B | 5.99M shrs $1.65B | |
| 3 |  AbbVie Inc. ABBV🇺🇸USD | $290.79 | +1.68% | +6.94% | $513.86B €460.01B | 4.3M shrs $1.25B | |
| 4 | Fr 410.00 | +0.15% | +0.97% | Fr 326.67B $365.87B · €327.53B | 3.55K shrs Fr 1.45M | ||
| 5 |  Merck & Co., Inc. MRK🇺🇸USD | $146.33 | +3.83% | +4.82% | $361.02B €323.19B | 13.42M shrs $1.96B | |
| 6 | Fr 402.20 | +0.12% | +1.11% | Fr 320.46B $358.91B · €321.30B | 235.84K shrs Fr 94.85M | ||
| 7 |  Novartis AG NVS🇺🇸USD | $161.10 | +3.22% | +0.50% | $304.26B €272.37B | 2.24M shrs $360.28M | |
| 8 |  Novartis AG NOVN.SW🇨🇭CHF | Fr 133.24 | +0.71% | +1.28% | Fr 251.64B $281.84B · €252.30B | 792.95K shrs Fr 105.65M | |
| 9 |  AstraZeneca PLC AZN🇺🇸USD | $174.40 | +2.88% | +1.57% | $270.48B €242.13B | 3.36M shrs $585.4M | |
| 10 |  AstraZeneca PLC AZN.L🇬🇧GBp | £1.34 | +2.99% | +1.94% | £208.47B $264.76B · €237.01B | 306.49K shrs £41.2M | |
| 11 |  Amgen Inc. AMGN🇺🇸USD | $460.73 | +1.97% | +4.13% | $249.09B €222.98B | 2.96M shrs $1.36B | |
| 12 | $165.61 | +4.03% | +0.74% | $205.35B €183.83B | 8.35M shrs $1.38B | ||
| 13 |  Novo Nordisk A/S NVO🇺🇸USD | $39.14 | +2.22% | +2.85% | $172.63B €154.54B | 10.34M shrs $404.61M | |
| 14 |  Pfizer Inc. PFE🇺🇸USD | $29.95 | +1.70% | -3.40% | $170.71B €152.82B | 28.77M shrs $861.71M | |
| 15 | $540.00 | +1.95% | +6.32% | $136.87B €122.53B | 1.54M shrs $829.69M | ||
| 16 | $61.39 | +1.35% | +1.64% | $125.4B €112.26B | 14.76M shrs $905.82M | ||
| 17 | €80.27 | +5.41% | -0.57% | €96.17B $104.82B | 1.13M shrs €91.03M | ||
| 18 | $43.13 | +2.11% | +0.07% | $103.35B €92.51B | 4.26M shrs $183.94M | ||
| 19 | $48.68 | -0.12% | -1.48% | $97.53B €87.31B | 5.2M shrs $253.14M | ||
| 20 | £0.18 | +1.98% | -1.40% | £74.13B $94.15B · €84.28B | 370.76K shrs £6.86M | ||
| 21 |  Moderna, Inc. MRNA🇺🇸USD | $222.76 | +4.01% | +18.85% | $88.93B €79.61B | 10.75M shrs $2.39B | |
| 22 | $818.77 | +0.68% | +1.08% | $84.3B €75.46B | 781.72K shrs $640.05M | ||
| 23 | ¥6822.00 | +2.54% | -1.07% | ¥11.23T $75.22B · €67.33B | 3.08M shrs ¥20.99B | ||
| 24 |  Merck KGaA MRK.DE🇩🇪EUR | €151.20 | +0.60% | — | €65.74B $71.65B | 10.11K shrs €1.53M | |
| 25 | ¥6651.00 | +2.78% | +3.33% | ¥10.62T $71.18B · €63.72B | 7.58M shrs ¥50.43B | ||
| 26 | $20.01 | -0.69% | +0.69% | $63.92B €57.22B | 4.77M shrs $95.48M | ||
| 27 |  CSL Limited CSL.AX🇦🇺AUD | A$200.73 | +1.64% | +2.40% | A$96.33B $62.61B · €56.05B | 1.33M shrs A$267.4M | |
| 28 | €281.00 | +0.36% | +2.46% | €53.58B $58.40B | 11.17K shrs €3.14M | ||
| 29 | $897.85 | +0.68% | +6.57% | $56.46B €50.55B | 160.88K shrs $144.45M | ||
| 30 | €802.20 | -0.27% | -2.39% | €50.45B $54.99B | 1.59K shrs €1.28M | ||
| 31 | €49.73 | +3.69% | — | €48.86B $53.25B | 911.97K shrs €45.35M | ||
| 32 | ₹1823.90 | +3.57% | -0.10% | ₹4.38T $52.51B · €47.01B | 2.94M shrs ₹5.36B | ||
| 33 | ₹1787.20 | +1.38% | — | ₹4.29T $51.46B · €46.06B | 104.12K shrs ₹186.08M | ||
| 34 | ¥249.24 | -1.75% | +14.82% | ¥368.62B $50.87B · €45.54B | 2.55M shrs ¥636.45M | ||
| 35 | Fr 190.90 | +0.63% | +2.03% | Fr 44.52B $49.86B · €44.63B | 63.08K shrs Fr 12.04M | ||
| 36 | ₩1487000.00 | +8.86% | +1.52% | ₩69.22T $49.84B · €44.62B | 99.34K shrs ₩147.72B | ||
| 37 | $41.47 | +3.75% | +0.69% | $48.37B €43.30B | 5.18M shrs $214.84M | ||
| 38 | ¥48.46 | -0.33% | +9.80% | ¥321.64B $44.39B · €39.73B | 60.43M shrs ¥2.93B | ||
| 39 | HK$50.70 | +0.10% | +5.28% | HK$336.51B $43.07B · €38.56B | 4.83M shrs HK$244.85M | ||
| 40 | $371.56 | -0.48% | +5.29% | $42.27B €37.84B | 268.14K shrs $99.63M | ||
| 41 | ¥12015.00 | -2.20% | +6.67% | ¥6.29T $42.17B · €37.75B | 2.07M shrs ¥24.92B | ||
| 42 | HK$221.40 | -0.36% | +5.71% | HK$327.45B $41.91B · €37.52B | 3.01M shrs HK$665.68M | ||
| 43 | $190.27 | +0.82% | +10.62% | $40.78B €36.51B | 1.32M shrs $251.65M | ||
| 44 | Fr 84.10 | +0.86% | +1.73% | Fr 36.39B $40.76B · €36.48B | 209.6K shrs Fr 17.63M | ||
| 45 | ₪1.29 | +1.18% | +2.45% | ₪150.1B $40.53B · €36.28B | 230.85K shrs ₪29.71M | ||
| 46 | $65.93 | +1.71% | +0.78% | $38.1B €34.10B | 2.45M shrs $161.55M | ||
| 47 |  Haleon plc HLN🇺🇸USD | $8.57 | -14.30% | +5.03% | $37.69B €33.74B | 57.71M shrs $494.59M | |
| 48 |  Biogen Inc. BIIB🇺🇸USD | $249.65 | +2.29% | +6.36% | $36.9B €33.04B | 1.16M shrs $289.03M | |
| 49 |  Haleon plc HLN.L🇬🇧GBp | £0.03 | +1.92% | +5.03% | £28.48B $36.17B · €32.38B | 3.07M shrs £9.94M | |
| 50 |  Genmab A/S GMAB🇺🇸USD | $56.49 | -1.40% | +6.55% | $34.74B €31.10B | 6.25M shrs $352.95M | |
| 51 |  Genmab A/S GMAB.CO🇩🇰DKK | kr 3796.00 | +0.21% | +5.36% | kr 233.42B $34.08B · €30.51B | 27.46K shrs kr 104.26M | |
| 52 | ¥2754.00 | +5.21% | +4.53% | ¥5.01T $33.58B · €30.06B | 13.51M shrs ¥37.21B | ||
| 53 |  Zoetis Inc. ZTS🇺🇸USD | $78.80 | +1.29% | -5.71% | $32.56B €29.15B | 2.93M shrs $231.26M | |
| 54 | ₩191600.00 | +1.22% | +2.26% | ₩43.69T $31.46B · €28.16B | 583.37K shrs ₩111.77B | ||
| 55 | ₹9832.50 | +1.75% | -2.99% | ₹2.61T $31.32B · €28.04B | 840.39K shrs ₹8.26B | ||
| 56 | ₹9801.85 | +1.52% | -3.57% | ₹2.6T $31.22B · €27.95B | 29.36K shrs ₹287.77M | ||
| 57 | ¥2571.00 | +2.31% | -0.93% | ¥4.61T $30.89B · €27.65B | 6.56M shrs ¥16.87B | ||
| 58 | $37.52 | +1.10% | +8.76% | $27.1B €24.26B | 3.73M shrs $139.9M | ||
| 59 | $593.54 | +1.20% | +0.52% | $25.46B €22.79B | 353.23K shrs $209.65M | ||
| 60 | HK$32.36 | -2.18% | +0.14% | HK$196.19B $25.11B · €22.48B | 7.82M shrs HK$253.11M | ||
| 61 | $111.59 | +15.06% | +4.75% | $24.37B €21.82B | 11.22M shrs $1.25B | ||
| 62 | $116.80 | -0.06% | +9.01% | $23.68B €21.19B | 3.04M shrs $355.52M | ||
| 63 | HK$44.48 | -1.29% | +12.56% | HK$183.09B $23.44B · €20.98B | 26.6M shrs HK$1.18B | ||
| 64 | $174.00 | -25.13% | +4.68% | $23.28B €20.84B | 11.8M shrs $2.05B | ||
| 65 |  BioNTech SE BNTX🇺🇸USD | $89.13 | +1.30% | +3.64% | $22.39B €20.04B | 692.04K shrs $61.68M | |
| 66 |  Viatris Inc. VTRS🇺🇸USD | $19.20 | +2.29% | +2.73% | $22.05B €19.74B | 10.49M shrs $201.45M | |
| 67 | ₹4605.50 | +0.56% | +2.81% | ₹1.75T $21.02B · €18.82B | 251.16K shrs ₹1.16B | ||
| 68 | ₹4597.70 | +0.74% | — | ₹1.56T $18.71B · €16.75B | 58.03K shrs ₹266.81M | ||
| 69 | HK$79.75 | -2.27% | +5.64% | HK$139.07B $17.80B · €15.94B | 11.9M shrs HK$948.9M | ||
| 70 | ¥3012.00 | +0.77% | -1.35% | ¥2.56T $17.18B · €15.38B | 3.77M shrs ¥11.35B | ||
| 71 | $253.00 | +1.38% | +12.24% | $16.65B €14.90B | 491.4K shrs $124.33M | ||
| 72 | kr 488.00 | +0.00% | +0.39% | kr 169.83B $16.47B · €14.75B | 14.46K shrs kr 7.06M | ||
| 73 |  Exelixis, Inc. EXEL🇺🇸USD | $66.20 | -0.12% | +5.10% | $16.4B €14.68B | 2.84M shrs $187.81M | |
| 74 | HK$38.10 | +5.89% | -3.07% | HK$121.52B $15.55B · €13.92B | 12.65M shrs HK$482.11M | ||
| 75 | ₹2384.30 | +6.25% | +0.83% | ₹1.29T $15.46B · €13.84B | 6.81M shrs ₹16.25B | ||
| 76 | ₹2382.00 | +6.10% | +4.00% | ₹1.29T $15.44B · €13.83B | 562.45K shrs ₹1.34B | ||
| 77 | NT$1190.00 | -4.03% | +24.20% | NT$492.32B $15.26B · €13.66B | 3.42M shrs NT$4.07B | ||
| 78 | €99.20 | +0.81% | +2.76% | €13.92B $15.18B | 14.19K shrs €1.41M | ||
| 79 | €99.00 | +0.92% | +2.32% | €13.88B $15.13B | 961 shrs €95.14K | ||
| 80 | $131.18 | +0.88% | +10.61% | $14.89B €13.33B | 1.87M shrs $245.9M | ||
| 81 | $146.38 | +0.58% | +3.92% | $14.88B €13.32B | 830.76K shrs $121.61M | ||
| 82 | ₹1234.40 | +4.22% | -0.27% | ₹1.23T $14.78B · €13.23B | 3.08M shrs ₹3.8B | ||
| 83 | ₹1228.95 | +3.62% | +2.26% | ₹1.23T $14.71B · €13.17B | 276.49K shrs ₹339.79M | ||
| 84 |  Ipsen S.A. IPN.PA🇫🇷EUR | €157.30 | +0.96% | +1.97% | €12.96B $14.13B | 6.09K shrs €957.96K | |
| 85 | ¥244.07 | +1.37% | +26.73% | ¥100.77B $13.91B · €12.45B | 1.93M shrs ¥470.26M | ||
| 86 | $70.73 | -0.13% | +8.58% | $13.83B €12.38B | 4.93M shrs $348.94M | ||
| 87 | ₹1354.90 | +0.74% | +2.97% | ₹1.13T $13.54B · €12.13B | 1.34M shrs ₹1.81B | ||
| 88 | ₹1353.15 | +1.09% | — | ₹1.13T $13.52B · €12.10B | 253.96K shrs ₹343.65M | ||
| 89 | $207.83 | +1.35% | +3.15% | $13.49B €12.08B | 773.56K shrs $160.77M | ||
| 90 | ₹1372.30 | +1.05% | +1.65% | ₹1.11T $13.30B · €11.91B | 1.03M shrs ₹1.42B | ||
| 91 | ₹1371.85 | +1.09% | — | ₹1.11T $13.30B · €11.90B | 17.26K shrs ₹23.68M | ||
| 92 | ¥53.71 | +1.47% | -1.15% | ¥95.83B $13.22B · €11.84B | 10.88M shrs ¥584.33M | ||
| 93 | HK$424.80 | -2.97% | +11.16% | HK$101.54B $13.00B · €11.63B | 695.26K shrs HK$295.35M | ||
| 94 | $16.20 | +2.73% | +0.91% | $12.92B €11.57B | 4.4M shrs $71.25M | ||
| 95 | ₹2497.40 | +1.14% | -1.51% | ₹1.03T $12.38B · €11.08B | 489.02K shrs ₹1.22B | ||
| 96 | ₹2493.80 | +1.32% | -1.85% | ₹1.03T $12.36B · €11.07B | 13.84K shrs ₹34.52M | ||
| 97 | €52.95 | -0.09% | — | €11.01B $12.00B | 3.57K shrs €189.08K | ||
| 98 | $14.11 | -0.28% | -2.24% | $11.75B €10.52B | 2M shrs $28.26M | ||
| 99 | ₹1673.60 | +1.12% | — | ₹973.51B $11.68B · €10.46B | 11.47K shrs ₹19.2M | ||
| 100 | $23.24 | +2.60% | +3.93% | $11.61B €10.39B | 3.49M shrs $81.02M |
Browse by Country
Europe
Asia